Biopharma | June 04, 2025
Sanofi exercises license extension option to Nurix’s STAT6 program
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Subscribe To Our Newsletter & Stay Updated
